Simplify Asset Management Inc. Takes Position in United Therapeutics Corporation $UTHR

Simplify Asset Management Inc. bought a new stake in United Therapeutics Corporation (NASDAQ:UTHR) in the third quarter, HoldingsChannel.com reports. The institutional investor bought 19,920 shares of the biotechnology company’s stock, valued at approximately $8,351,000. United Therapeutics comprises about 0.2% of Simplify Asset Management Inc.’s investment portfolio, making the stock its 16th largest holding.

Several other institutional investors and hedge funds have also bought and sold shares of the stock. Chung Wu Investment Group LLC purchased a new position in United Therapeutics in the 2nd quarter worth approximately $29,000. WealthCollab LLC increased its stake in shares of United Therapeutics by 55.9% in the second quarter. WealthCollab LLC now owns 106 shares of the biotechnology company’s stock worth $30,000 after buying an additional 38 shares during the period. Rakuten Securities Inc. increased its stake in shares of United Therapeutics by 76.7% in the second quarter. Rakuten Securities Inc. now owns 106 shares of the biotechnology company’s stock worth $30,000 after buying an additional 46 shares during the period. Geneos Wealth Management Inc. boosted its position in United Therapeutics by 141.7% during the 1st quarter. Geneos Wealth Management Inc. now owns 145 shares of the biotechnology company’s stock valued at $45,000 after buying an additional 85 shares during the period. Finally, Elevation Point Wealth Partners LLC purchased a new stake in United Therapeutics during the 2nd quarter valued at $53,000. 94.08% of the stock is currently owned by institutional investors.

Insider Activity

In other news, COO Michael Benkowitz sold 22,500 shares of the business’s stock in a transaction that occurred on Monday, October 13th. The stock was sold at an average price of $440.35, for a total value of $9,907,875.00. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Insiders have sold 602,664 shares of company stock worth $279,087,286 in the last ninety days. 10.30% of the stock is currently owned by company insiders.

Analyst Ratings Changes

A number of brokerages have issued reports on UTHR. Wells Fargo & Company raised their price target on shares of United Therapeutics from $414.00 to $423.00 and gave the stock an “equal weight” rating in a report on Thursday, October 30th. UBS Group raised their target price on United Therapeutics from $580.00 to $600.00 and gave the stock a “buy” rating in a research note on Thursday, November 6th. Weiss Ratings reaffirmed a “buy (b)” rating on shares of United Therapeutics in a research report on Monday, December 22nd. Royal Bank Of Canada lifted their price objective on United Therapeutics from $569.00 to $587.00 and gave the stock an “outperform” rating in a research report on Thursday, October 30th. Finally, Jefferies Financial Group reissued a “buy” rating and set a $575.00 target price on shares of United Therapeutics in a research note on Wednesday, November 19th. Eight equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $505.00.

United Therapeutics Stock Performance

Shares of NASDAQ:UTHR opened at $502.90 on Tuesday. The firm has a market capitalization of $21.65 billion, a P/E ratio of 19.06, a P/E/G ratio of 5.04 and a beta of 0.86. The stock has a 50 day moving average price of $472.78 and a 200-day moving average price of $390.12. United Therapeutics Corporation has a 52-week low of $266.98 and a 52-week high of $519.99.

United Therapeutics (NASDAQ:UTHR) last issued its quarterly earnings results on Wednesday, October 29th. The biotechnology company reported $7.16 earnings per share for the quarter, topping the consensus estimate of $6.89 by $0.27. The company had revenue of $799.50 million for the quarter, compared to analysts’ expectations of $812.87 million. United Therapeutics had a return on equity of 18.83% and a net margin of 40.65%.The firm’s revenue for the quarter was up 6.8% on a year-over-year basis. During the same period in the prior year, the firm earned $6.39 earnings per share. On average, equities analysts forecast that United Therapeutics Corporation will post 24.48 EPS for the current fiscal year.

United Therapeutics Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.